TCT-596 Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience – Results from CENTURY II trial

Background: The impact of ticagrelor-based dual antiplatelet therapy (DAPT) on acute coronary syndrome (ACS) in patients with chronic kidney disease (CKD) remains unclear.Methods: Data on a total of 1,067 ACS patients with CKD including end-stage renal disease (ESRD) who underwent new-generation drug-eluting stent implantation were extracted from a multicenter registry. This study aimed to compare outcomes of patients treated with ticagrelor- (n = 449) and those treated with clopidogrel-based (n = 618) DAPT. Outcomes of interest included major adverse cardiac and cerebrovascular events (MACCEs) and bleeding (Bleeding Academic Research Consortium grade 3 or 5) at 12 months. Propensity-score matching (346 pairs) analysis was performed.Results: The patients with ESRD showed the highest MACCE and bleeding rates (P < 0.001). There was no difference in the rate of MACCEs between the treatment groups (7.8% vs. 8.4%; hazard ratio [HR] = 0.95, 95% confidence interval [CI] = 0.56–1.61, P = 0.855); however, a trend toward an increased bleeding rate was observed in the ticagrelor-based DAPT group (6.8% vs. 3.8%, HR = 1.84, 95% CI = 0.93–3.63, P = 0.079). Among patients with CKD stage III/IV but without ESRD (277 pairs), the ticagrelor-based DAPT group showed a reduced MACCE rate (3.6% vs. 8.7%, HR = 0.41, 95% CI = 0.19–0.86, P = 0.018) and a similar bleeding rate (5.1% vs. 3.2%, HR = 1.61, 95% CI = 0.70–3.71, P = 0.267), compared with those of the clopidogrel-based DAPT group.Conclusion: The effects of ticagrelor-based DAPT on ischemic and bleeding outcomes of ACS patients with CKD varied according to CKD stage; in ACS patients with CKD without ESRD, ticagrelor-based DAPT reduced MACCE risk without increasing bleeding risks, relative to those observed with clopidogrel-based DAPT.

Download Full-text

CLINICAL OUTCOMES AFTER TREATING ACUTE CORONARY SYNDROME PATIENTS WITH A DRUG-ELUTING STENT: RESULTS FROM REWARDS-EMI (ENDEAVOR FOR MYOCARDIAL INFARCTION REGISTRY)

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(12)60375-1 ◽

2012 ◽

Vol 59 (13) ◽

pp. E374

Author(s):

Danny Dvir ◽

Israel Barbash ◽

Rebecca Torguson ◽

Zhenyi Xue ◽

Salem Badr ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Clinical Outcomes ◽

Drug Eluting Stent ◽

Coronary Syndrome ◽

Drug Eluting

Download Full-text

Short and long terms clinical outcomes of Paclitaxel drug-eluting balloons applied for de-novo coronary artery lesions in the context of acute coronary syndrome: a real world experience

Indian Heart Journal ◽

10.1016/j.ihj.2021.03.011 ◽

2021 ◽

Author(s):

Ahmed Ayuna ◽

Sherif Seif ◽

John MacDonald ◽

Ayyaz Sultan

Keyword(s):

Acute Coronary Syndrome ◽

Coronary Artery ◽

Clinical Outcomes ◽

Real World ◽

De Novo ◽

Coronary Artery Lesions ◽

Coronary Syndrome ◽

Drug Eluting

Download Full-text

Endovascular Treatment with Limus Eluting Stents in Patients with Acute Coronary Syndrome

Russian Sklifosovsky Journal Emergency Medical Care ◽

10.23934/2223-9022-2019-8-1-45-52 ◽

2019 ◽

Vol 8 (1) ◽

pp. 45-52

Author(s):

M. V. Chernyayev ◽

A. G. Faybushevich ◽

Y. S. Muzganova

Keyword(s):

Coronary Heart Disease ◽

Acute Coronary Syndrome ◽

Heart Disease ◽

Drug Therapy ◽

Fatal Outcome ◽

Drug Eluting Stent ◽

Health State ◽

Medium Term ◽

Coronary Syndrome ◽

Drug Eluting

BACKGROUND Coronary heart disease is one of the main causes of the population’s disability and mortality in Russia and abroad. Revascularization with coronary stents in the course of the most suitable drug therapy is one of the most important treatments of coronary heart disease. It is essential to pay special attention to the research results of using modern stents, in particular, the frst Russian drug-eluting stent “CALYPSO”.AIM OF STUDY To study immediate and medium-term results of Limus-eluting stents procedure in patients with acute coronary syndrome.MATERIAL AND METHODS 304 patients with acute coronary syndrome were included into the research and were divided into 2 groups. The frst group consisted of 156 patients with CALYPSO stent (Angioline, Russia). The other group consisted of 148 patients who had undergone revascularization with the XIENCE stent (Abbot Vascular, USA). Their health state was monitored via phone 3, 6, 9 and 12 months later. After the discharge from the hospital, the drug therapy was prescribed, and instrumental procedures of diagnostics were planned for the period of 9–12 months. According to the results of the examination, patients with suspected or confrmed myocardial ischemia underwent follow-up coronary angiography.RESULTS The success of implantation was 98.63% in the frst group, and 99.4% in the second group. One fatal outcome occurred in both groups during hospitalization (thus making 0.64% и 0.67%). The placement of the CALYPSO stent in distal parts of coronary arteries requested signifcantly less time and contrast. Medium-term results of stenting in both groups appeared to be comparable (thus, all cause death 3 (1.92%) and 2 (1.35%), restenosis >50% 3 (1.92%) and 3 (2 %), late thrombosis — 0 in both groups, cardiac death — 0 in both groups. End points (MACE) in both groups were 1.28% and 0.67%.CONCLUSION Taking into consideration immediate and medium-term results it can be concluded that domestic stents (CALYPSO) are comparable to stents XIENCE. The CALYPSO stent is more advantageous than the XIENCE in the delivery to the lesion focus while performing the procedure in distal ﬂow.

Download Full-text